ACHIEVE-4, the longest Phase 3 study of Eli Lilly's (LLY) Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health

Eli Lilly's Phase 3 study results for Foundayo reaffirm its cardiovascular safety and cardiometabolic health, which supports its future FDA submission.

Newsquawk StaffPublished On the live feed at 3 more headlines followed before this page went public
Newsquawk headlinesUTC

IEA Chief Birol says Europe has maybe 6 weeks left of jet fuel, AP reports; warns of possible flight cancellations soon if oil supplies remain blocked by the war

Iranian Parliamentary Speaker Ghalibaf says the ceasefire in Lebanon is as important to us as the ceasefire in Iran

ACHIEVE-4, the longest Phase 3 study of Eli Lilly's (LLY) Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health

Marsh (MRSH) Q1 2026 (USD): Adj. EPS 3.29 (exp. 3.23), Revenue 7.6bln (exp. 7.41bln)

Intertek (ITRK LN) rejects indicative cash proposal from EQT on April 10 and is mulling options

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • FDA submission planned by end-Q2.
Context

This positive outcome could enhance investor confidence and drive valuation, especially in light of competitive pressures in the pharmaceuticals sector.

Related headlines

The whole workspace, free to try.

Try it free